quinacrine has been researched along with Disease Exacerbation in 4 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD)." | 1.32 | Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. ( Alpérovitch, A; Belorgey, C; Boher, E; Brandel, JP; Delasnerie-Lauprêtre, N; Faucheux, BA; Haïk, S; Hauw, JJ; Laplanche, JL; Salomon, D; Sazdovitch, V; Soubrié, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Ong, WY | 1 |
| Lu, XR | 1 |
| Horrocks, LA | 1 |
| Farooqui, AA | 1 |
| Garey, LJ | 1 |
| Pauri, F | 1 |
| Amabile, G | 1 |
| Fattapposta, F | 1 |
| Pierallini, A | 1 |
| Bianco, F | 1 |
| Haïk, S | 1 |
| Brandel, JP | 1 |
| Salomon, D | 1 |
| Sazdovitch, V | 1 |
| Delasnerie-Lauprêtre, N | 1 |
| Laplanche, JL | 1 |
| Faucheux, BA | 1 |
| Soubrié, C | 1 |
| Boher, E | 1 |
| Belorgey, C | 1 |
| Hauw, JJ | 1 |
| Alpérovitch, A | 1 |
4 other studies available for quinacrine and Disease Exacerbation
| Article | Year |
|---|---|
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Induction of astrocytic cytoplasmic phospholipase A2 and neuronal death after intracerebroventricular carrageenan injection, and neuroprotective effects of quinacrine.
Topics: Animals; Astrocytes; Carrageenan; Cell Death; Disease Progression; Enzyme Induction; Gliosis; Inject | 2003 |
Sporadic Creutzfeldt-Jakob disease without dementia at onset: clinical features, laboratory tests and sequential diffusion MRI (in an autopsy-proven case).
Topics: 14-3-3 Proteins; Brain; Creutzfeldt-Jakob Syndrome; Dementia; Diagnosis, Differential; Diffusion Mag | 2004 |
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
Topics: Brain; Creutzfeldt-Jakob Syndrome; Disease Progression; Drug Evaluation; Humans; Quinacrine; Surviva | 2004 |